MTOR and metabolic dysfunction-associated steatohepatitis: Nevertheless, pharmaceutical enhancement of autophagy by rapamycin or carbamazepine which inhibits mTOR reduced hepatic steatosis in NASH model [107], and severe hepatic steatosis occurs in mice with hepatic deletion of Atg5 [104].